Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 1.76B 1.53B 1.43B 1.31B 2.46B 168B 2.5B 16.78B 6.58B 84.23B 6.62B 6.48B 281B P/E 2026 *
-3.75x
P/E 2027 * -3.82x
Enterprise Value 1.35B 1.17B 1.09B 996M 1.87B 128B 1.91B 12.8B 5.01B 64.23B 5.05B 4.94B 214B EV / Sales 2026 *
26.3x
EV / Sales 2027 * 21.6x
Free-Float
97.69%
Yield 2026 *
-
Yield 2027 * -
1 day+1.82%
1 week+1.21%
Current month+11.67%
1 month+1.52%
3 months+2.76%
6 months-9.70%
Current year-18.09%
1 week 3.01
Extreme 3.01
3.42
1 month 2.84
Extreme 2.84
3.54
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
29.4
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer 57 2026-04-05
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap.
8/4/26 Sell

Founder

-30,000 0.0057%
7/7/26 Sell

Founder

-40,000 0.0076%
7/1/26 Free

Founder

3,747 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+1.82%+1.21%-36.67%-64.99% 1.76B
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+3.71%+31.77%+63.89% 55.41B
-1.62%+34.25%+17.43%+491.04% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
0.00%+1.59%-15.06%-13.21% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-3.08%-8.34%+37.21%+138.52% 13.12B
Average +0.36%+276.75%+49.84%+177.25% 26.95B
Weighted average by Cap. -0.39%+192.26%+54.91%+163.44%

Financials

2026 *2027 *
Net sales 51.19M 44.36M 41.53M 37.89M 71.31M 4.88B 72.51M 487M 191M 2.44B 192M 188M 8.15B 67.79M 58.75M 55M 50.18M 94.43M 6.47B 96.02M 645M 253M 3.24B 255M 249M 10.8B
Net income -459M -398M -372M -340M -639M -43.76B -650M -4.36B -1.71B -21.9B -1.72B -1.68B -73.07B -474M -411M -385M -351M -661M -45.24B -672M -4.51B -1.77B -22.65B -1.78B -1.74B -75.55B
Net Debt -419M -363M -340M -310M -583M -39.95B -593M -3.98B -1.56B -20B -1.57B -1.54B -66.71B -298M -259M -242M -221M -416M -28.46B -423M -2.84B -1.11B -14.24B -1.12B -1.1B -47.52B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-08-11 US$3.350 +1.82% 10,949,159
26-08-10 US$3.290 +2.17% 14,034,778
26-08-07 US$3.220 +1.26% 9,355,889
26-08-06 US$3.180 +0.32% 14,794,378
26-08-05 US$3.170 -4.23% 17,458,815
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.290USD
Average target price
7.250USD
Spread / Average Target
+120.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock